

Notícia sobre as atividades do Projeto Fight-2


Notícia nº 15



10 de Novembro de 2021

A equipa do Projecto Fight-two participa na 1ª Conferência Albedo Vaccines Meet, 4 a 6 de Novembro de 2021

A equipa do Projecto Fight-Two participou no 1st International Albedo Meet on Vaccines (Vaccine Meet 2021), que decorreu de 4 a 6 de novembro de 2021 em Nice, França. Esta conferência reuniu participantes de vários continentes, que partilharam resultados de investigação em temas relacionados com desenvolvimento de vacinas para agentes patogénicos e para combate ao cancro, estudos de resposta a vacinação e outros no campo da medicina humana e da medicina veterinária. Carina Carvalho (investigadora do INIAV e do Projecto Fight-Two) proferiu uma apresentação intitulada “*Fight-Two Project: development of a vaccine against RHDV2 in the wild rabbit*”, partilhando os outputs do Projecto Fight-2 alcançados até à data. O Projeto suscitou a curiosidade e o interesse da assistência.



Carina Carvalho, na 1st International Albedo Meet on Vaccines, 5 de novembro 2021.

Projeto Fight-Two – Desenvolvimento de vacina edível para o controlo da doença hemorrágica viral (RHDV2) nos coelhos-bravos

PTDC/CVT-CVT/29062/2017-PT2020 - Fundação para a Ciência e Tecnologia

Notícia sobre as atividades do Projeto Fight-2

Notícia nº 15



10 Novembro de 2021

A equipa do Projecto Fight-two participa na 1ª Conferência Albedo Vaccines Meet, 4 a 6 de Novembro de 2021



VACCINESMEET2021

NOVEMBER 04-05, 2021 | NICE, FRANCE

Location: Park Inn by Radisson
Nice Airport, Nice, France

Final Program



ALBEDO MEETINGS

Floor# 3, Advant Building, 99B, Kakatiya
Hills, Kavuri Hills, Madhapur Hyderabad,
TS 500033
Email: contact@albedomeetings.com

Day 1 | November 04, 2021

09:00-09:15	OnSpot Registrations
	Meeting Room: Mirage
09:15-09:30	Opening Ceremony
	Plenary Session
09:30-10:10	P Title: Live Attenuated Pertussis Vaccine and Its Off-Target Effects: From Concept to Clinical Development Camille Loch, French National Institute of Health and Medical Research, France
10:10-10:50	P Title: Personalized and Precision Medicine (PPM) as a Unique Healthcare Model to be Set up via Translational Applications and Upgraded Business Modeling to Secure the Human Healthcare, Wellness and Biosafety: The Next-Step Vaccinology on the Way to Move Ahead Sergey Suchkov, Moscow University, Russia
10:50-11:05	Coffee Break: Foyer
11:05-11:45	P Title: Warburg Effect, Lactate, Acidity and Immune-Responses Jacques Pouyssegur, University of Cole d'Azur, Nice, France
11:45-12:25	P Title: Cervical Cancer and Its Relationship with Hpv and the Vaccine for this Virus Maria de Lourdes da Silva Marques Ferreira, University of Sao Paulo, Brazil
12:25-13:05	P Title: Cholera Vaccines and Global Roadmap for Ending Cholera by 2030 Jan Holmgren, University of Gothenburg, Sweden
13:05-13:10	Group Photo
13:10-14:00	Lunch: Restaurant
14:00-14:40	P (Online) Title: Immunogenic Cell Death: Two Inducers are Better than One John Milburn Jessup, Research & Development Division, USA
14:40-15:20	P Title: Antibodies (Abs) with Functionality (Ab-Proteases) as a New Generation of Translational Tools designed get Healthcare Model Re-Armed Sergey Suchkov, Moscow University, Russia
15:20-16:00	P (Online) Title: mRNA Vaccination: The Days of Future Past Robert W Malone, RW Malone, USA
16:00-16:15	Coffee Break: Foyer
	Invited Session
	Session:1 COVID-19 Vaccines Anti-Viral Vaccines Others
	Session Chair: Suma Alluri, Avalon University, Netherlands Antilles
16:15-16:40	I Title: Vaccines Against Covid 19 Suma Alluri, Avalon University, Netherlands Antilles
16:40-17:05	I Title: Development of a Prototype Oral Vaccine for the Control of RHDV2 in the Wild Rabbit Carina Luisa da Costa Carvalho, INIAV, Portugal

17:05-17:30	I Title: COVID-19 Vaccine Candidates Based on Modified Vaccinia Virus Ankara Expressing the SARS-Cov-2 Spike Induce Robust T- And B-Cell Immune Responses and Full Efficacy in Mice Juan Garcia-Arriaza, Centro Nacional de Biotecnología, Spain
17:30-17:55	I Title: Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins Adrian Lazaro-Frias, Centro Nacional de Biotecnología, Spain
	End of Day 1 Conference
	Day 2 November 05, 2021
	Meeting Room: Mirage
	Session:2 Vaccine and Immunizations Vaccine Research & Development
	Session Chair: Vega Masignani, GSK Vaccines, Italy
10:00-10:25	I Title: From Reverse Vaccinology to Real World Evidence Data: the Long Journey to the Development of a New Vaccine against serogroup 9 Meningococcal Disease Vega Masignani, GSK Vaccines, Italy
10:25-10:50	I Title: Coronavirus Vaccines – A Blueprint for other Vaccine Developments? Larseder Grode, Vekina Projekt Management GmbH, Germany
10:50-11:15	I Title: Deconstructing Polyclonal Antibody Responses at the Molecular Level Using cryoEM Andrew Ward, Scripps Research, USA
11:15-11:30	Coffee Break: Foyer
11:30-11:55	I Title: Germine-Encoded Viral Recognition Lingwood Daniel, The Ragion Institute, USA
	Session:3 Cancer Vaccines Infectious & Non-Infectious Diseases
	Session Chair: Amina Kadi, Laboratory of Medical Biology, France
11:55-12:20	I Title: Kinetics of the Humoral Response After SARS-Cov-2 Vaccination With BNT162b2 (Pfizer-Biontech) In Gonesse Hospital's Healthcare Workers Amina Kadi, Laboratory of Medical Biology, France
12:20-12:45	I Title: Safety of Covid-19 Vaccines, Showing Some Interesting Cases of Rare Adverse Events Artur Cieslewicz, Poznan University of Medical Sciences, Poland
12:45-13:10	I Title: Effect Of Covid-19 On Post-Vaccination Immunity In Healthcare Workers Robert Flisiak, Medical University of Białystok, Poland
13:10-14:00	Lunch: Restaurant
	Virtual Presentations
14:00-14:25	I Title: Specific Protection Status Against Diphtheria and Measles in Adults Living in Latvia Ludmila Vikena, Riga Stradins University, Latvia
14:25-14:50	I Title: Hyaluronid Acid Nanogel (HANG)-based Cancer Vaccine Hiroshi Shiku, Mie University Graduate School of Medicine, Japan

14:50-15:15	I Title: Designing Next-Generation DNA-Launched Nanoparticle Vaccines for Enhanced Cellular Immunity Against Melanoma Ziyang Xu, University of Pennsylvania, USA
15:15-15:40	I Title: Reduction of Mucosal Infection in Humanized Mice by Non-Neutralizing Antibodies against HIV-1 Envelope Hioe Catarina, Icahn School of Medicine at Mount Sinai, USA
15:40-16:05	I Title: Will be updated soon Yun Beom Sang, CHA University School of Medicine, Seongnam, South Korea
16:05-17:00	Poster Presentations and Coffee Break
P001	Poster Title: The Combined Vaccination Protocol Of Dna/Mva Expressing Zika Virus Structural Proteins As Efficient Inducer Of T And B Cell Immune Responses Patricia Perez, Centro Nacional de Biotecnología, Spain
P002	Poster Title: Detection of Antibody Responses against SARS-CoV-2 in Plasma and Saliva from Vaccinated and Infected Individuals Jeromine Klingler, Icahn School of Medicine at Mount Sinai, USA
	End of the Conference

VACCINESMEET2022

2ND INTERNATIONAL MEET ON VACCINES

DECEMBER 05-07, 2022 | LONDON, UK

Website Link: <https://albedomeetings.com/vaccinesmeet/2022/>

Projeto Fight-Two – Desenvolvimento de vacina edível para o controlo da doença hemorrágica viral (RHDV2) nos coelhos-bravos

PTDC/CVT-CVT/29062/2017-PT2020 - Fundação para a Ciência e Tecnologia